Challenges and New Developments in Metastatic Colorectal Cancer With Tanios Bekaii-Saab, MD

Despite the many obstacles associated with treating and managing patients with metastatic colorectal cancer, the ongoing study of several novel agents has the potential to significantly improve the outcomes of these patients in the coming years. In this interview, Tanios Bekaii-Saab, MD, Professor of Medicine at the Mayo Clinic Cancer Center in Phoenix, Arizona, discusses strategies to optimize the management of metastatic colorectal cancer and the promising developments which may advance treatm...
Continue reading

Time to Treatment Initiation Impacts Survival in Common Cancers

In patients with common cancers, a longer time to treatment initiation is associated with higher all-cause mortality, according to results of a cohort study now published in JAMA Network Open. "The COVID-19 pandemic has forced many hospitals in the US to grapple with decisions on how best to optimize allocation of limited health care resources," write the investigators, led by Eugene B. Cone, MD, of the Division of Urological Surgery at Brigham and Women's Hospital. "Postponing particular cancer...
Continue reading

Shortened Oxaliplatin-Based Chemo Course Reduces Neuropathy Risk

Oxaliplatin-based chemotherapy, while effective, can cause peripheral sensory neuropathy (PSN)—an incurable, debilitating condition in which peripheral nerve damage occurs and causes muscle weakness, pain, and pins and needles sensation, among other symptoms—in patients with stage III colon cancer. However, researchers recently discovered that a shortened three-month course of adjuvant oxaliplatin-based chemotherapy reduces the risk of PSN in patients with stage III colon cancer. For this study,...
Continue reading

Colorectal Cancer Diagnoses on the Rise in Younger Patients

Researchers from the University of Texas at Austin have determined that diagnoses of colorectal cancer are increasing in patients under 50 years of age. While new guidelines from the American Cancer Society recommend that average-risk adults begin undergoing regular screening for colorectal cancer at age 45, many physicians do not begin referring patients for screening – either colonoscopy or alternatives such as fecal immunochemical tests or fecal occult blood tests – until age 50. The study pu...
Continue reading

Ad5-GUCY2C-PADRE Colon Cancer Vaccine Effective in Humans

A phase I clinical trial reports that the cancer vaccine Ad5-GUCY2C-PADRE produces an immune response with minimal adverse events in patients with early-stage colorectal cancer. Colorectal cancer is the fourth most common cancer and the second leading cause of cancer death worldwide. Of the two-thirds of patients who undergo surgical resection with curative intent, 30% to 50% experience disease recurrence and die as a result of their cancer. Since adjuvant chemotherapy has no clinical benefit in...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.